19:20 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

CX3CL1 gene therapy for retinitis pigmentosa

DISEASE CATEGORY: Ophthalmic disease INDICATION: Retinitis Mouse studies suggest CX3CL1 gene therapy could help treat retinitis pigmentosa. In three mouse models of retinitis pigmentosa, CX3CL1 encoded in an adeno-associated viral (AAV) serotype 8 (AAV8) vector...
16:18 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers showing that lymphoma, inflammation and cardiovascular disease candidate KAND567 (AZD8797) was well tolerated. The double-blind, placebo-controlled trial evaluated single doses of...
15:44 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest CX3CL1 could help treat obesity. In a mouse model of diet-induced obesity, female mice had high levels of CX3CL1 in the hypothalamus and gained less weight than male mice, which...
23:51 , Feb 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cytomegalovirus (CMV) Studies in cells suggest a bacterial toxin-based inhibitor of US28 could help treat latent CMV infection. In a human monocyte cell line expressing US28, a fusion protein consisting of the US28-binding chemokine...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CMV CC chemokine receptor (US28)

Infectious disease INDICATION: Cytomegalovirus (CMV) In vitro and mouse studies identified a bacterial toxin-based inhibitor of US28 that could help treat human cytomegalovirus (HCMV) infection. Chemical synthesis and in vitro testing of chemokine-toxin fusion proteins...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Chemokine CX3C motif receptor 1 (CX3CR1); chemokine CX3C motif ligand 1 (CX3CL1; fractalkine) In vitro and mouse studies suggest antagonizing CX3CR1 or preventing cleavage...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); HER2 (EGFR2; ErbB2; neu) Mouse studies suggest inhibiting CX3CL1 could help treat...
07:00 , May 2, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); chemokine CX3C motif receptor 1 (CX3CR1) In vitro and mouse studies suggest...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine) Mouse studies suggest the soluble isoform of CX3CL1 could help treat PD. In a mouse...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia; reperfusion injury Chemokine CX3C motif ligand1 (CX3CL1; fractalkine) Rodent studies suggest CX3CL1 could help decrease ischemia-induced tissue damage. In a mouse model of...